Haemonetics Stock News

Haemonetics Corporation (NYSE: HAE) posted Q3 FY22 sales of $259.77 million, +8% Y/Y, missing the consensus of $ $266.74 million. Organic revenue was down 0.8%. The Company posted an adjusted EPS o

Haemonetics Corporation (NYSE: HAE ) posted Q3 FY22 sales of $259.77 million , +8% Y/Y, missing the consensus of $ $266.74 million. Organic revenue was down 0.8%. The Company posted an adjusted EPS of $0.84, up 3.7% compared to Q3 FY21, beating the consensus of $0.73. Plasma segment sales declined 5.4% Y/Y (-2.0% organically) to $96.46 million, Blood Centre unit sales fell 6.5% (-7.3%) to $ 75.69 million, and Hospital segment sales increased 56.3% (10.5%) to $82.27 million. The adjusted … Full story available on Benzinga.com

US stocks remained mostly higher on Tuesday, while the S&P 500 traded lower by 0.1%. Midway through trading Tuesday, the Dow traded up 0.20% to 35,161.03 while the NASDAQ rose 0.14% to 14,035.14. The S&P, however, fell 0.10% to 4,479.38. Check out this: Apple And 3 Other Stocks Sold By Insiders Leading and Lagging Sectors Materials shares rose by 0.9% on Tuesday. Meanwhile, top gainers in the sector included Century Aluminum Company (NASDAQ: CENX ), up 13% and Alcoa Corporation (NYSE: AA ) up 12%. In trading on Tuesday, energy shares tumbled by 2.1%. Top Headline Pfizer Inc. (NYSE: PFE ) posted better-than-expected earnings for its fourth quarter, while sales missed estimates. Pfizer posted quarterly earnings of $1.08 per share, beating analysts’ estimates of $0.87 per share. The company’s quarterly sales came in at $23.80 billion, versus market expectations of $24.20 billion. Pfizer said it sees FY22 adjusted earnings of $6.35 to $6.55 per share. Equities Trading UP American Rebel Holdings, Inc. (NASDAQ: AREB ) shares shot up 43% to $3.1566 following uplisting to Nasdaq on Monday.

Gainers Society Pass Incorporated (NASDAQ: SOPA ) gained 63.4% to $3.45 after dropping 16% on Monday. American Rebel Holdings, Inc. (NASDAQ: AREB ) climbed 56.1% to $3.45 following uplisting to Nasdaq on Monday. Tritium DCFC Limited (NASDAQ: DCFC ) surged 23.1% to $8.42 following tweet from US President Biden ''I''m looking forward to hosting the folks from Tritium at the White House today. Like manufacturers large and small, they''re creating good-paying jobs building the future'' Teradata Corporation (NYSE: TDC ) shares gained 21.6% to $48.97 after the company issued Q1 EPS guidance above estimates and raised FY21 EPS guidance above estimates. Atomera Incorporated (NASDAQ: ATOM ) surged 19.1% to $16.68. Atomera said it has licensed its Mears Silicon Technology to a semiconductor foundry. uCloudlink Group Inc. (NASDAQ: UCL ) shares climbed 18.8% to $1.7575. The company, last month, reported a private placement of $5.0 million convertible debentures. Haemonetics Corporation (NYSE: HAE ) gained 14.1% to $53.61 following upbeat Q3 earnings.

Haemonetics Corporation (NYSE:HAE) Q3 2022 Results Conference Call February 08, 2022 08:00 AM ET Company Participants Olga Guyette - Director, IR Christopher Simon - President, CEO William

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Axsome To Pay $312,500 To Settle Patent Infringement Litigation With Baudax Axsome Therapeutics, Inc.

Haemonetics Corporation HAE posted Q3 FY22 sales of $259.77 million, +8% Y/Y, missing the consensus of $ $266.74 million. Organic revenue was down 0.8%.

Haemonetics (HAE) delivered earnings and revenue surprises of 12% and 2.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics Corporation (HAE) CEO Christopher Simon on Q3 2022 Results - Earnings Call Transcript

Haemonetics (HAE) delivered earnings and revenue surprises of 12% and 2.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Haemonetics Corp. (HAE) shares closed 7.0% lower than its previous 52 week low, giving the company a market cap of $2B. The stock is currently down 10.6% year-to-date, down 60.2% over the past 12 months, and up 20.9% over the past five years. This week, the Dow Jones Industrial Average fell 2.5%, and the S&P 500 fell 4.1%. Trading Activity Trading volume this week was 14.4% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 24.2% The company's stock price performance over the past 12 months lags the peer average by -506722.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 232.4% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Haemonetics Corp. (HAE) shares closed today at 0.7% above its 52 week low of $47.06, giving the company a market cap of $2B. The stock is currently down 7.2% year-to-date, down 60.0% over the past 12 months, and up 24.1% over the past five years. This week, the Dow Jones Industrial Average fell 3.0%, and the S&P 500 fell 4.8%. Trading Activity Trading volume this week was 32.2% higher than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -8.1% The company's stock price performance over the past 12 months lags the peer average by 87459.7% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 243.4% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

The Thromboelastography Market report focus on the current trends of the request along with detailed analysis which provides data regarding this request rate, and it also predicts the unborn request growth rate. The Thromboelastography Market study includes exploration on the